The President – COO and CMO of Paratek Pharmaceuticals, Inc. (PRTK), Evan Loh Sold 8,084 Shares of the Company; Enbridge Energy Management L L C (EEQ) Sentiment Is 1.42

April 11, 2018 - By Martha Paddon

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Logo

Sentiment for Enbridge Energy Management L L C (EEQ)

Enbridge Energy Management L L C (EEQ) investors sentiment increased to 1.42 in Q4 2017. It’s up 0.13, from 1.29 in 2017Q3. The ratio has increased, as 68 hedge funds opened new and increased equity positions, while 48 sold and decreased equity positions in Enbridge Energy Management L L C. The hedge funds in our database now possess: 64.37 million shares, up from 61.31 million shares in 2017Q3. Also, the number of hedge funds holding Enbridge Energy Management L L C in top ten equity positions decreased from 1 to 0 for a decrease of 1. Sold All: 16 Reduced: 32 Increased: 50 New Position: 18.

The stock increased 3.40% or $0.31 during the last trading session, reaching $9.43. About 854,232 shares traded or 11.58% up from the average. Enbridge Energy Management, L.L.C. (EEQ) has declined 45.19% since April 11, 2017 and is downtrending. It has underperformed by 56.74% the S&P500.

Enbridge Energy Management, L.L.C., through its limited partner interests in Enbridge Energy Partners, L.P., owns and operates crude oil and liquid petroleum transportation and storage assets in the United States. The company has market cap of $868.13 million. It also owns and operates natural gas gathering, treating, processing, transportation, and marketing assets in the United States. It currently has negative earnings.

Energy Income Partners Llc holds 3.29% of its portfolio in Enbridge Energy Management, L.L.C. for 14.33 million shares. Eagle Global Advisors Llc owns 4.25 million shares or 1.78% of their US portfolio. Moreover, Kayne Anderson Capital Advisors Lp has 1.69% invested in the company for 9.90 million shares. The Texas-based Salient Capital Advisors Llc has invested 1.61% in the stock. Karpas Strategies Llc, a New York-based fund reported 184,815 shares.

The stock increased 0.39% or $0.05 during the last trading session, reaching $12.95. About 422,615 shares traded. Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has declined 26.88% since April 11, 2017 and is downtrending. It has underperformed by 38.43% the S&P500.

Analysts await Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) to report earnings on May, 3. They expect $-0.95 EPS, up 16.67% or $0.19 from last year’s $-1.14 per share. After $-0.78 actual EPS reported by Paratek Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 21.79% negative EPS growth.

Evan Loh, an insider of Paratek Pharmaceuticals Inc, currently President – COO and CMO lately disclosed a trade with the (SEC). According to the legal report, Evan Loh made a sale of 8,084 shares of the Pinksheet-listed Paratek Pharmaceuticals Inc, priced at $12.7 per share. $102,667 US Dollars was the trade’s value. The SEC report’s date was 10-04-2018. Evan Loh owns 0.68% of the -company’s market cap or 214,786 shares.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. The company has market cap of $407.19 million. The Company’s lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections , community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. It currently has negative earnings. The firm has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP.

Among 10 analysts covering Paratek Pharmaceuticals (NASDAQ:PRTK), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Paratek Pharmaceuticals has $55 highest and $23 lowest target. $42.44’s average target is 227.72% above currents $12.95 stock price. Paratek Pharmaceuticals had 27 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, July 18. The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has “Outperform” rating given on Thursday, October 27 by Leerink Swann. Gabelli initiated Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) rating on Thursday, July 23. Gabelli has “Buy” rating and $34 target. The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) earned “Buy” rating by H.C. Wainwright on Friday, June 17. Zacks downgraded the shares of PRTK in report on Saturday, August 8 to “Hold” rating. The firm has “Buy” rating given on Thursday, September 21 by Robert W. Baird. The firm has “Outperform” rating by Wedbush given on Tuesday, April 4. The company was maintained on Monday, July 17 by Cantor Fitzgerald. On Thursday, March 1 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Leerink Swann maintained Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) on Thursday, June 15 with “Buy” rating.

Enbridge Energy Management, L.L.C. (NYSE:EEQ) Institutional Positions Chart